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Abstract
Purpose Patients with a cardiac implantable electronic device
(CIED) often need device interrogation in an in-hospital envi-
ronment. A diagnosis-only, remote interrogation device and
process for CIED interrogation was developed to address this
situation. Here, we describe our initial clinical experience with
this system.
Methods The LATITUDE Consult Communicator is a stand-
alone interrogation-only device used to read the patient’s im-
planted CIED. Once retrieved, the data are securely transmit-
ted via an analog phone line to a central server. The clinician
can request a review of the transmitted data at any time.
Following FDA approval, we determined the usage and per-
formance of the system.
Results Communicators (n=53) were installed in 42 hospital
facilities. The most common location was in the emergency
department (n=32, 60 %). There were 509 discreet transmis-
sions, which were categorized as follows: no arrhythmia epi-
sodes in the past 72 h and no out of range measurements
(n=174, 34 %); arrhythmia episodes in past 72 h but no out
of range measurements (n=170, 33 %); and further review
recommended (n = 130, 26 %). (In 35 [7 %] instances,
interrogation without analysis was requested.) The further re-
view interrogations were then sub-divided into those of a non-
urgent and urgent nature. Overall, only 53 (10 %) of the 509
transmissions were classified as urgent. Clinicians had access
to full technical consultation in ≤15 min in 89 % of instances.
Conclusion Our data demonstrate the feasibility of a new di-
agnosis-only, remote interrogation device and remote evalua-
tion process for the interrogation of CIEDs in an in-hospital
environment.
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Abbreviations
AHP allied health professional
CIED cardiac implantable electronic device
CRT cardiac resynchronization therapy
ED emergency department
FDA Food and Drug Administration
HCP healthcare professional
ICD implantable cardioverter-defibrillator
IEAP industry-employed allied professional
IQR interquartile range
PACU post-anesthesia care unit
PPM permanent pacemaker
Several hundred thousand patients undergo cardiac implant-
able electronic device (CIED) implantation in the USA annu-
ally [1, 2]. Recommendations for the routine follow-up of
these devices, either through in-person evaluation or through
remote monitoring, have recently been updated [1, 3].
However, patients often need device interrogation outside
the elective environment to determine device settings, to
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assess the cause for an implantable cardioverter-defibrillator
(ICD) shock, and/or to monitor surrogate markers of physio-
logic performance. Common scenarios include patients with a
CIED presenting to the emergency department (ED) and those
undergoing surgery or radiotherapy. In the case of the latter,
device evaluation is often needed both immediately before
and after intervention.
The responsibility for these non-elective device checks has
fallen on industry-employed allied professionals (IEAPs) and/
or trained physicians/allied health professionals (AHPs).
However, unscheduled in-person interrogations impose a ma-
jor challenge for workflow and come at the cost of delayed
diagnosis and additional healthcare utilization. Furthermore, it
has been previously shown that the vast majority of patients
who present for device interrogation require no change to their
medications or device reprogramming [4]. Given the develop-
ment of remote monitoring technology and current clinical
guidelines that recommend remote monitoring as the preferred
method for routine CIED follow-up, we hypothesized that
similar technology could be used and would be of value to
interrogate devices quickly in an in-hospital environment and
provide the clinician with a rapid initial review of findings.
Thus, a diagnosis-only, remote interrogation device and re-
mote evaluation process for CIEDs was developed to address
this situation. To date, there have been no published reports of
using remote monitoring to facilitate the triage of CIED pa-
tients who require device interrogation. The purpose of this
study is to describe our initial clinical experience with this
system.
1 Methods
The LATITUDE Consult system provides access to expert
technical review of data retrieved from an implanted Boston
Scientific CIED without requiring on-site access to a Boston
Scientific programmer or representative from Boston
Scientific or trained healthcare professional (HCP) (e.g.,
AHP/physician) expert in CIED interrogation. This system
requires minimal training for its use and is designed for use
in locations such as the ED, radiation center, pre- and post-
operative surgical units, hospital floors, and satellite clinics
(including heart failure clinics).
The LATITUDEConsult Communicator (Fig. 1) is a stand-
alone interrogation device used to read the patient’s implanted
device via a telemetry wand placed over the patient’s device.
In this manner, it is possible to interrogate compatible perma-
nent pacemakers (PPM), implantable cardioverter defibrilla-
tors (ICD), cardiac resynchronization therapy (CRT) pace-
makers, and CRT defibrillators manufactured by Boston
Scientific. The system can only read data; it cannot reprogram
the device, perform commanded lead tests (such as pacing
threshold tests or impedance measurements), or change any
functions of the implanted device. Once retrieved from the
device, upon command from the user, the data may be secure-
ly transmitted via an analog phone line to the Boston
Scientific LATITUDE Server. For security, at the end of the
process, the data are erased from the LATITUDE Consult
Communicator itself.
To use the LATITUDE Consult system, the HCP or patient
places the attached wand over the implanted device and
presses the blue BStart Action^ button. This begins the device
interrogation process; the Communicator creates an inductive
link with the implanted device and determines the model of
the device. The stored data on the device are downloaded onto
the Communicator internal storage (Table 1). On command by
the user, by pressing the Continue/Send prompt on the LCD
touchscreen, the data are securely transmitted via an analog
phone line to Boston Scientific LATITUDEConsult Technical
Services. The status of this process is pictorially shown via a
series of LCD screens on the Communicator (Fig. 2) for the
user.
After transmission of the implanted device data, the clini-
cian can call LATITUDE Consult Technical Services 24 h a
day, 7 days a week to request an expert technical review of the
transmitted data and obtain a report of the interrogation. The
clinician provides his/her name, the patient’s name, the model/
serial number of the implanted device, the location of the
interrogation, the reason for interrogation, and a phone num-
ber for an optional callback. The device data can be immedi-
ately reviewed by the Technical Services consultant, and the
following reports can be sent via e-mail and/or fax for clini-
cian review and entry into the patient’s medical records: (1)
Transmission Report; (2) Quick Notes Report; (3) Combined
Follow-up Report; (4) Presenting Electrogram Report; (5)
Arrhythmia Logbook Report; (6) Event Detail/Episodes
Report ; and (7) Device Set t ings Report (Online
Supplementary Material).
The clinician can discuss the reviewed implanted device
data live with a trained US-based LATITUDE Consult
Technical Services consultant either real-time with no need
for a callback or after the LATITUDE Consult Technical
Services representative performs a detailed review and calls
back to discuss the data. Based on the findings of the interro-
gation, the local Boston Scientific technical representative can
be contacted in order to provide additional consultation and/or
perform reprogramming with the device programmer.
Alternatively, for centers with regular usage of the
LATITUDE Consult system, clinicians may opt to have de-
vice reports auto sent to a designated e-mail and/or fax number
after the device data are successfully uploaded. In this scenar-
io, the transmission report is sent to the clinician for review
without analysis from a LATITUDE Consult Technical
Services consultant.
All transmissions were cataloged into one of three catego-
ries based on the device data retrieved from the Consult
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Fig. 1 LATITUDE Consult Communicator
Table 1 Device data transmitted
for review during the LATITUDE
Consult interrogation process
Downloaded data Common values
Status messages Status message displayed as applicable to indicate the current
status of the device and/or leads as of the latest device
transmission
Stored episodes Stored episodes which occurred within the prior 72 h based
on the type of device and programmed settings. Arrhythmia
logbook contains all episodes available in the device at the time
of upload
Battery status Battery status as of the latest device transmission
Lead measurements Most recent daily lead measurements for applicable chambers
that are programmed on (e.g., intrinsic amplitude, pace
impedance, pace threshold, shock impedance)
Trend graphs Up to 12 months of all applicable leads, events, and health trends
based on device type and programmed settings
Ventricular tachy counters Counters for different types of tachy episodes based on the type
of device and programmed settings
Pacing counters, histograms,
and rate counts
Number of paced and sensed beats for applicable chambers (e.g.,
atrial, right ventricular, and left ventricular) since the last device
reset and reset before the last in counter, histogram, and rate
count formats
Device settings Brady mode, pacing outputs, rate enhancements, and tachy
therapy zones if applicable
Therapy mode, if applicable Monitor, monitor + therapy, off
Presenting EGM 10 or 30 s of presenting intercardiac electrogram tracings based
on the type of device
tachy tachycardia
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transmission and discussion with the clinician. The first cate-
gory was one with no device or arrhythmia concerns. The
second category included patients who had an arrhythmia,
who received therapy as programmed, and where the device
was functioning appropriately. The final category included
patients where further review of the CIED system was recom-
mended either due to concerns about the device or when
reprogramming was suggested to optimize device settings.
These were further sub-classified into urgent and non-urgent
transmissions. They were labeled urgent if the physician re-
quired immediate in-person analysis of the CIED by an IEAP
or trained HCP with a programmer for possible device
reprogramming. In non-urgent cases, the treating physician
determined that further CIED follow-up was not necessary
on an immediate basis and could wait for normal clinic hours
in the event of an after-hours event or wait for a scheduled or
walk-in appointment at the device clinic.
Following FDA approval of the LATITUDE Consult
System in March 2014, a limited market release was per-
formed with additional data recorded in order to evaluate the
usage and performance of the system. The first Communicator
was placed into service in May 2014; additional
Communicators were brought online over the next year.
Each Communicator had a discreet serial number, which
allowed tracking of location from where each transmission
emanated. We determined whether transmissions were occur-
ring within business hours, defined as between 8 AM and 6
PM within that institution’s time zone from Monday–Friday,
or outside business hours. Supplemental data on the perfor-
mance of and reason for LATITUDE Consult uses was col-
lected and logged into a Boston Scientific database for later
analysis. The data collected are listed in Supplementary
Table 1.
2 Results
Ultimately, 53 unique Communicators were installed in 42 hos-
pital facilities across the USA. We included facilities serving a
variety of different populations in 20 states. In addition, of the
42 facilities involved in this study, 22 %were academic centers
and 82 % were non-profit institutions. Seven (13 %) centers
were located in an area with a population density of <100
persons per square mile, 20 (38 %) centers were located in an
area with a population density between 100 and 999 persons
per square mile, and 26 (49 %) centers were located in areas
with a population density of >1000 persons per square mile. In
any given facility, there were 1–4 Communicators stored in
discreet locations. The three most common locations for the
Communicators were in the ED (n=32, 60 %), the post-
anesthesia care unit (PACU; n=8, 15 %), and a satellite clinic
(n=8, 15 %; Table 2). The median duration during which an
individual center had access to the LATITUDE Consult
Communicator was 4 months (interquartile range (IQR) 2, 7).
The first transmission was obtained in May 2014; the final
transmission was received in March 2015. During this time
period, there were 509 discreet transmissions analyzed from a
LATITUDE Consult Communicator. The median number of
transmissions from any center was 3 (IQR 2, 14).
Transmissions most commonly originated from the ED
(n=294, 58 %) or the PACU (n=145, 28 %; Table 2). The
most common reasons for device check were for evaluation of
patient symptoms, a post-procedure check, and for evaluation
of a shock (Table 2). Transmissions were used to evaluate an
ICD in 39 % of patients, a CRT-ICD in 30 % of patients, a
PPM in 30 % of patients, and a CRT-PPM in 1 % of patients.
The average number of transmissions per center was 9
(median=3, IQR=2–14). Transmissions were grouped into
Fig. 2 LATITUDE Consult
Communicator screens providing
status of the interrogation and
data transmission process
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four categories based on the indication for device interroga-
tion and analysis of the data, as shown in Fig. 3. Further
review was recommended in 130 patients (see Table 3), in
which the consulting physician requested immediate in-
person analysis of the CIED by a trained IEAP or HCP with
a programmer in 53 cases; the remaining 77 cases recom-
mended analysis by an in-person IEAP or HCP with a pro-
grammer, but the analysis could wait until a scheduled or
walk-in appointment. There were 170 transmissions in which
arrhythmias occurred but were appropriately treated, and no
further in-person analysis of the CIED was necessary. In 174
cases, no arrhythmia episodes were recorded in the CIED and
no out-of-range measurements were observed which eliminat-
ed the need for an in-person evaluation of the device. In an
additional 35 (7 %) instances, an interrogation only without
analysis of the device data was requested. Overall, only 53
(10 %) of the 509 transmissions were classified as urgent; 51
(96 %) of these urgent transmissions originated from the ED.
Thus, for 90 % of all device interrogations, it was possible
to triage patients as having either normal device function or
findings that did not require immediate attention. This is sig-
nificant from a workflow perspective as 154 (57 %) emergen-
cy department transmissions and 4 (29 %) of hospital floor
transmissions occurred outside of traditional business hours;
in contrast, transmissions from the PACU, radiation center,
heart failure clinic. and satellite clinics largely originated dur-
ing business hours, reflecting their usual hours of operation.
The after-hours or weekend transmissions resulted in 25 ur-
gent follow-up recommendations (24 in the emergency de-
partment and 1 on the hospital floor).
We assessed the efficiency of this approach to device inter-
rogation during the initial 254 transmissions. In 130 (51 %) of
these 254 transmissions, real-time review of the device inter-
rogation was requested and provided. This means that the
clinician stayed on the line with Boston Scientific Technical




















































































































































































































































































































































Fig. 3 Categorization of all 509 LATITUDE Consult transmissions
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of the device interrogation. In the other 124 (49%) transmis-
sions, the clinician requested a callback from Technical
Services. This was achieved in 13.9 ± 6.3 min (range 2–
44 min). In 89 % of instances, this was accomplished in
15 min or less. Delays in callback were accounted for either
by the HCP being busy or by the presence of significant events
that required extensive time for complete review. As an exam-
ple, in the review that took 44 min, the patient had 9 episodes
during which 16 shocks were delivered to the point that ther-
apy had been exhausted.
3 Discussion
This manuscript has several important findings. Foremost, for
the first time, we have demonstrated the feasibility of a new
diagnosis-only, remote interrogation device and remote eval-
uation process for the interrogation of all types of CIEDs
(albeit from a single device manufacturer) in an in-hospital
environment without the requirement of an on-site IEAP or
trained physicians/AHPs. Second, the system could be utilized
in a variety of settings both during and after traditional busi-
ness hours. Importantly, in 89 % of instances, data analysis
could be accomplished either in real time or within 15 min.
Third, in 90 % of instances, the interrogation showed that no
urgent device intervention was necessary for the management
of the patient. This enables appropriate resources to efficiently
be directed to the 10% of patients with a significant finding on
initial device interrogation.
Interrogation of CIEDs is essential to ensure the integrity of
the hardware, to assess the adequacy of device programming
relative to the patient’s clinical needs, and to monitor the
physiologic and diagnostic data stored within the device.
Historically, this has been accomplished through in-office de-
vice interrogations. However, more than a decade ago, tech-
nology became available that permitted remote follow-up of
CIEDs from a patient’s home. Initially, guidelines recom-
mended that device follow-up could be accomplished through
in-office or remote interrogations [1]. With time, there was
significant improvement in and acceptance of remote moni-
toring technology [5]. By reducing burdensome, non-
actionable in-person office visits and streamlining workflow,
remote monitoring of CIEDs can reduce the burden imposed
by the Bdramatic increase in the number of implants in the last
decade [6, 7].^ As a result, the most recent guidelines advo-
cate the use of remote monitoring in preference to routine
calendar-based in-office device interrogations [3].
However, to date, there has been little attention paid to the
burden posed to patients, IEAPs, and HCPs when patients
require unscheduled device interrogations in an in-hospital
environment. Guidelines recommend that if an IEAP is re-
quested to evaluate a pacemaker or ICD in the hospital, the
physician who made the request should be immediately avail-
able by phone if he or she cannot provide direct supervision
[8]. However, the guidelines are otherwise silent on the burden
posed by these in-hospital device interrogations.
We hypothesized that modification of existing remotemon-
itoring technology could be employed in an in-hospital envi-
ronment. The Communicators used in this study were capable
of interrogating most Boston Scientific CIEDs, irrespective of
device type. Once the HCP initiated the interrogation, a report
was provided similar to what would be available were the
device interrogated using a programmer. Depending on the
preference of the HCP, an interpretation of the interrogation
Table 3 Interrogations requiring
further review: characterization
into non-urgent and urgent
categories
Non-urgent (n= 77)
Syncope but no episodes and no out-of-range measurements observed 22 (29 %)
Settings may be considered for programming optimization, e.g., PMT,
RYTHMIQ, SBR, ATP, LV, sensors
18 (23 %)
Atrial arrhythmia episodes 16 (21 %)
New non-sustained episodes 12 (16 %)
Stored episodes older than 72 h are not uploaded by LATITUDE Consult,
therefore not available for review
5 (6 %)
Low RV intrinsic amplitude or gradual rise in shock lead impedance 4 (5 %)
Urgent (n= 53)
Multiple ATP and/or shocks delivered; therapy may be considered for optimization 18 (34 %)
Possible clinically inappropriate therapy; therapy may be considered for optimization 10 (19 %)
Rhythm detected in zone where therapy is not programmed; therapy may be
considered for optimization
8 (15 %)
RVor LV intermittent capture or possible oversensing 7 (13 %)
Patient symptoms that may be arrhythmia related, e.g., PPM with tachycardia
episodes, ICD with no therapy programmed
7 (13 %)
Possible battery depletion 3 (6 %)
ATP antitachycardia pacing, ICD implantable cardioverter-defibrillator, LV left ventricular, PMT pacemaker-
mediated tachycardia, PPM permanent pacemaker, RV right ventricular, SBR sudden bradycardia response
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could be left to the provider or be performed by a trained
Boston Scientific employed technician. Irrespective, data
were available quickly (most commonly within 15 min)
allowing patients to be triaged in an efficient manner.
This has particular importance in settings like the ED
where capacity and throughput are continually challenged
[9, 10]. The ED is frequently the site for unscheduled device
checks. As an example, 83 (97 %) of the 86 transmissions in
this study to evaluate an ICD shock were initiated in the ED.
In 76 % of these instances, transmissions occurred outside of
traditional business hours. Even in this cohort, it was possible
to determine quickly and efficiently that in 60 % of patients,
no further immediate device-related intervention was
necessary.
Another important utilization of the system is pre- and
post-intervention when interrogations are necessary (e.g., ad-
ministration of radiotherapy, following a surgical procedure
using electrocautery) to ensure adequate functioning of the
CIED [11, 12]. There were 171 such transmissions in this
study. It was determined that no further immediate device-
related intervention was necessary in 170 (>99 %) of these
instances. Prior to the availability of this system, a patient
would have to wait pre- and post-procedure for someone to
interrogate the device. Alternatively, an IEAP performed the
pre-procedure device interrogation and then waited for the
procedure to complete to perform a post-procedure interroga-
tion. In addition to the inconvenience to patients, this results in
tremendous waste of time and resources, especially given that
almost all patients have normally functioning devices.
Limitations This manuscript has a few limitations. First, once
the system was installed in any location within a participating
hospital, all subsequent interrogations of a compatible Boston
Scientific pacemaker or defibrillator at that location were
intended to be performed using this remote interrogation sys-
tem. However, there is no way to exclude entirely that an
IEAP or other HCPs performed a device interrogation using
a standard device programmer for initial device evaluation
during this time period. Second, as this was a pilot study, we
did not have a comparative group of patients who underwent
device interrogations using a customary programmer-based
approach. This would have occurred when a device interroga-
tion occurred in a hospital location where there was no
communicator.
Conclusions Our data suggest that interrogation of CIEDs
coupled to a remote server in various hospital-based clinical
settings is clinically feasible and can be performed quickly
and efficiently. Based on clinical experience, it is self-
evident that device interrogation could not have been achieved
in a similar time frame had we relied on the usual practice of
using an IEAP or trained physicians/AHP. However, in the
future, formal cost-effectiveness analysis comparing this
approach with the usual IEAP/HCP programmer-based device
interrogations in an in-hospital environment can be consid-
ered. The availability of data transfer usingWi-Fi connectivity
as well as directly over the cellular network will likely en-
hance the ability of this technology to operate efficiently irre-
spective of the local hospital environment. Future efforts
should be directed towards using this type of technology rou-
tinely when CIED patients require device evaluation in an in-
hospital environment.
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